Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
- Ono to Consolidate US, European Operations to Deciphera
March 3, 2025
- Over 60% of Doctors Have Prejudices about Obesity: Lilly/Mitsubishi Survey
March 3, 2025
- GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
March 3, 2025
- Eisai Licenses Tasfygo to SciClone in Greater China Region
March 3, 2025
- Chiome Inks Research Collab Pact with OmniAb
March 3, 2025
- Cariprazine Broadens Label in Thailand: Mitsubishi Tanabe
March 3, 2025
- 2-Dose Vial of COVID Vaccine Filed in Japan: Meiji
March 3, 2025
- Higher-Dose Regimen of Spinraza Filed in Japan: Biogen
March 3, 2025
- Some Generics See Lower Profit Margins, Return to LLPs after Elective Care Rollout
February 28, 2025
- FRONTEO to Provide AI-Based Drug Discovery Support Service in US
February 28, 2025
- AstraZeneca Rolling Out “Unify” App for Decentralized Trials in Japan
February 27, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…